In this article, we will discuss the 10 best dividend stocks to buy according to Sculptor Capital. You can skip our detailed analysis of the hedge fund and its developments, and go directly to read 5 Best Dividend Stocks to Buy According to Sculptor Capital.
Sculptor Capital, formerly known as OZ Capital Management, is a publicly listed asset management firm. It was founded by Daniel Och in 1994, who stepped down from his position as the CEO of the fund in 2019. Currently, Jimmy Levin is serving as the Chief Investment Officer and CEO of Sculptor Capital.
Sculptor Capital manages roughly $38 billion in assets. Sculptor Capital was one of the funds that benefitted during the pandemic. The hedge fund’s Credit Opportunities Fund gained 17% in 2021 by investing in beaten-down assets, as reported by Bloomberg. As of 2022, the hedge fund is down 17.04%.
As of Q3 2021, Sculptor Capital holds a 13F portfolio value of over $12.1 billion. The hedge fund invests in technology, services, finance, and healthcare stocks. Some of the hedge fund’s major holdings in Q3 are Amazon.com, Inc. (NASDAQ:AMZN), Netflix, Inc. (NASDAQ:NFLX), and Tesla, Inc. (NASDAQ:TSLA).
Our Methodology:
In this article, we will focus on the dividend stocks in Sculptor Capital’s portfolio. For this list, we considered Sculptor Capital’s 13F portfolio as of Q3.
10 Best Dividend Stocks to Buy According to Sculptor Capital
10. Becton, Dickinson and Company (NYSE:BDX)
Number of Hedge Fund Holders: 51
Dividend Yield as of February 4: 1.29%
Sculptor Capital’s Stake Value: $31,103,000
Becton, Dickinson and Company (NYSE:BDX), an American medical technology company, is one of the Dividend Aristocrats as 2021 marked the company’s 50th consecutive year of dividend growth. In 2021, the company increased its dividend by 4.8% at $0.87 per share, with a dividend yield of 1.29%.
As per Insider Monkey’s Q3 data, 51 hedge funds held stakes in Becton, Dickinson and Company (NYSE:BDX), down from 52 in the previous quarter. The total value of these stakes is over $2.33 billion. Among these hedge funds, Generation Investment Management was the company’s largest stakeholder in Q3, holding shares worth over $932.8 million.
Madison Funds mentioned Becton, Dickinson and Company (NYSE:BDX) in its Q2 2021 investor letter. Here is what the firm has to say:
“Becton, Dickinson and Company (“BD”) is one of the world’s largest medical supply, devices, laboratory equipment, and diagnostic products manufacturers. We like BD because it is a leader in the medical and life science industries with a durable mid-single digit growth profile and attractive returns on capital. They generate about 85% of revenue from consumables and 15% from equipment, and each year, they manufacture billions of needles, syringes, catheters, tubes, and medical devices which results in significant economies of scale that can be matched by few competitors. Their Life Sciences segment produces products that provide diversity in the steadily growing diagnostic testing and life sciences research fields.
Regarding the short-term issues, it’s been a challenging past 18 months for the company. In February 2020, they announced the FDA required an updated 510(k) clearance for their Alaris infusion pump. As a result, BD had to suspend selling new pumps until the updated regulatory filing received FDA clearance. In addition to the regulatory headwind, BD’s business was negatively impacted by the COVID-19 pandemic as individuals postponed doctor office visits and hospitals deferred non-emergency medical procedures. We believe these postponements are just now normalizing. Lastly, while BD’s Life Sciences business swiftly brought COVID-19 tests to market, there is uncertainty over the magnitude and duration of these revenues.
We believe these negative dynamics will be resolved over time, and meanwhile, base business growth and managerial actions should move per share earnings power higher. First, BD’s management is confident that the Alaris infusion pump has maintained its market share over the last 18 months and many hospitals have even added to their fleet of pumps with BD shipping them under medical necessity provisions. The new 510(k) filing was submitted in April 2021 and is expected to receive approval sometime in the next year, which will fully alleviate the concern. Second, we believe that hospital utilization and diagnostic testing volumes will return towards normal levels as vaccination rates increase and global economies reopen (the U.S. is reportedly currently at 95% and 100% utilization for inpatient and outpatient volumes, respectively). While COVID testing revenues (about 10% of 2021 BD revenue) are expected to decline, management’s choice to accelerate the depreciation of those production assets and to spend a portion of the excess 2021 profits will dampen the earnings cyclicality. Base diagnostic testing revenue will otherwise recover with patient volumes, and combination flu-COVID tests will help maintain some COVID testing revenues into the future. Third, BD’s balance sheet has improved markedly over the past year, and we expect them to reinitiate share repurchases at a meaningful level. This will lead to the first material share count reductions since 2014.
At today’s share price, we deem this to be value-creative capital allocation. Fourth, BD recently announced its intention to spin off its slower-growing diabetes business in 2022; our observations in recent years suggest that separations such as this have been value-creative for health care investors. Fifth, this year’s earnings quality is high by dint of management underutilizing its production assets to lean out inventories and to accelerate its R&D programs, both which positively impact future cash earnings power. Thus, while there is near-term uncertainty regarding the resolution of the issues mentioned, we think they’ll resolve. We believe that management’s actions and the resumption of base demand leave BD positioned to return to a good long-term growth profile.
The stock trades at less than 19x Wall Street’s consensus earnings estimate for 2022, which is approximately 90% of the earnings multiple of the S&P 500 and an even steeper discount to BD’s medical technology peer group. We think the stock is attractively priced and a good value for a leader in the growing medical technology and life science industries.”
9. Stanley Black & Decker, Inc. (NYSE:SWK)
Number of Hedge Fund Holders: 37
Dividend Yield as of February 4: 1.81%
Sculptor Capital’s Stake Value: $53,373,000
Stanley Black & Decker, Inc. (NYSE:SWK) is an American tool and storage company that also manufactures security products. In Q3 2021, Sculptor Capital held shares worth $53.3 million in the company, after increasing its stake by 4%. Stanley Black & Decker, Inc. (NYSE:SWK) constituted 0.44% of the hedge fund’s portfolio in Q3.
Stanley Black & Decker, Inc. (NYSE:SWK) has been paying dividends to shareholders for the past 54 years while maintaining a 50-year streak of dividend growth. The company’s 5-year dividend growth rate stands at 5.69%, which is considered safe among Wall Street analysts.
In February, Citigroup’s analyst Eric Lau expressed his concern over supply chain issues but asserted that Stanley Black & Decker, Inc. (NYSE:SWK) is well-positioned to overcome such constraints. The analyst resumed its coverage on the stock with a Buy rating and a $215 price target.
In Q3 2021, 37 hedge funds tracked by Insider Monkey were reported owning stakes in Stanley Black & Decker, Inc. (NYSE:SWK), valued at over $776 million. In the previous quarter, 44 hedge funds held stakes in the company.
Saturna Capital mentioned Stanley Black & Decker, Inc. (NYSE:SWK) in its Q3 2021 investor letter. Here is what the firm has to say:
“Stanley Black &Decker performed well through the first part of the year but struggled over the summer. China accounts for much of its production, and their zero-tolerance approach to pandemic safety measures has led to disruption, compounded by shipping difficulties and rising materials expenses. We still believe one outcome of the pandemic will be a buoyant home improvement market, given that one never knows when the next pandemic lockdown may occur.”
8. Bank of America Corporation (NYSE:BAC)
Number of Hedge Fund Holders: 72
Dividend Yield as of February 4: 1.81%
Sculptor Capital’s Stake Value: $398,218,000
Bank of America Corporation (NYSE:BAC) is an American multinational financial services company and an investment bank. On February 3, JPMorgan highlighted the bank’s loan growth and recovery in consumer spending in its investors’ note. The firm lifted its price target on Bank of America Corporation (NYSE:BAC) to $53.50, while maintaining an Overweight rating on the shares.
The number of hedge funds tracked by Insider Monkey having stakes in Bank of America Corporation (NYSE:BAC) declined to 72 in Q3, from 87 in the previous quarter. These stakes hold a consolidated value of over $46.4 billion. Warren Buffett’s Berkshire Hathaway was the company’s largest shareholder in Q3, with shares worth over $42.8 billion.
In 2021, Bank of America Corporation (NYSE:BAC) increased its dividend by 17% at $0.21 per share. Bank of America Corporation (NYSE:BAC) was the fourth-largest holding of Sculptor Capital in Q3, as the hedge fund increased its stake in the company by 24% during the quarter. The company represented 3.28% of the fund’s 13F portfolio.
Oakmark Funds mentioned Bank of America Corporation (NYSE:BAC) in its Q3 2021 investor letter. Here is what the firm has to say:
“Earlier this year, one of our holdings, Bank of America, announced that it was raising its minimum hourly wage from $15 to $20 and would increase it to $25 by 2025. The company received great press for placing the well-being of its employees above profits. But was it really either/or? Bank of America Corporation (NYSE:BAC)’s chief human resources officer spoke to the bigger picture: “A core tenet of responsible growth is our commitment to being a great place to work…that includes providing strong pay and competitive benefits to help them and their families, so that we continue to attract and retain the best talent.” Bank of America Corporation (NYSE:BAC) understood that engaged, high-caliber employees are more productive, less prone to turnover and, therefore, less expensive in the long run. Increasing the pay for employees wasn’t elevating employees above shareholders; it was the right thing to do for employees and for shareholders.
If an increase to $20 was good, why stop there? Why not $50 per hour? Because the benefits the business receives at $50 don’t justify the expense. The bank would no longer be able to price its products competitively and would lose business. The employees would “win” in the short term, but eventually the lost business would lead to job cuts, meaning both employees and shareholders would lose. The negative effects of stakeholder overreach are no different than when CEOs overreach to inflate short-term profits. Both hurt shareholders and stakeholders.”
7. NextEra Energy, Inc. (NYSE:NEE)
Number of Hedge Fund Holders: 53
Dividend Yield as of February 4: 2.03%
Sculptor Capital’s Stake Value: $95,069,000
Sculptor Capital started investing in NextEra Energy, Inc. (NYSE:NEE), an American energy company, during the third quarter of 2019. In Q3 2021, the hedge fund increased its stake in the company by 12% and owned shares worth over $95 million. NextEra Energy, Inc. (NYSE:NEE) made up 0.78% of the hedge fund’s portfolio.
This December, BMO Capital raised its price target on NextEra Energy, Inc. (NYSE:NEE) to $98, with an Outperform rating on the shares. The company has been raising dividends consistently for the past 26 years, falling into the category of Dividend Aristocrats. In 2021, NextEra Energy, Inc. (NYSE:NEE) increased its quarterly dividend by 10% to $0.385 per share, with a dividend yield of 2.03%.
At the end of Q3 2021, 53 hedge funds tracked by Insider Monkey reported owning stakes in NextEra Energy, Inc. (NYSE:NEE), down from 59 in the previous quarter. The total value of these stakes is over $2.37 billion.
6. Himax Technologies, Inc. (NASDAQ:HIMX)
Number of Hedge Fund Holders: 18
Dividend Yield as of February 4: 2.57%
Sculptor Capital’s Stake Value: $3,582,000
Himax Technologies, Inc. (NASDAQ:HIMX) is a semiconductor manufacturer based in Taiwan. Sculptor Capital held a stake worth $3.5 million in Himax Technologies, Inc. (NASDAQ:HIMX) as of Q3.
Currently, Himax Technologies, Inc. (NASDAQ:HIMX) pays a quarterly dividend of $0.27 per share, up 170% from the previous dividend of $0.10 per share.
At the end of Q3 2021, the number of hedge funds tracked by Insider Monkey having positions in Himax Technologies, Inc. (NASDAQ:HIMX) increased to 18, from 16 in the preceding quarter. The total value of these stakes is over $206 million. Among these hedge funds, Renaissance Technologies was one of the company’s major shareholders in Q3, holding a stake worth $16.8 million.
Click to continue reading and see 5 Best Dividend Stocks to Buy According to Sculptor Capital.
Suggested articles:
- 10 Best Vanguard Stocks to Buy Now
- 10 Best Stocks Under $10 to Buy Right Now
- 10 Best Technology Stocks That Pay Dividends
Disclosure. None. 10 Best Dividend Stocks to Buy According to Sculptor Capital is originally published on Insider Monkey.
